A5102379017- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Immune cells in cancer
- RNA Research and Splicing
- HVDC Systems and Fault Protection
- Epigenetics and DNA Methylation
- RNA Interference and Gene Delivery
- Cancer Cells and Metastasis
- Liver physiology and pathology
- Cell death mechanisms and regulation
- RNA and protein synthesis mechanisms
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Circular RNAs in diseases
- Nanoplatforms for cancer theranostics
- Galectins and Cancer Biology
- Heat shock proteins research
- Cancer, Hypoxia, and Metabolism
- Wnt/β-catenin signaling in development and cancer
- Phagocytosis and Immune Regulation
Sun Yat-sen University
2020-2025
Zhengzhou University
2024
China-US (Henan) Hormel Cancer Institute
2024
Background and Aims Hypoxia is a common feature of the tumor microenvironment (TME), which promotes progression, metastasis, therapeutic drug resistance through myriad cell activities in stroma cells. While targeting hypoxic TME emerging as promising strategy for treating solid tumors, preclinical development this approach lacking study HCC. Approach Results From genome‐wide CRISPR/CRISPR‐associated 9 gene knockout screening, we identified aldolase A (ALDOA), key enzyme glycolysis...
Objective Dysregulated cellular metabolism is a distinct hallmark of human colorectal cancer (CRC). However, metabolic programme rewiring during tumour progression has yet to be fully understood. Design We analysed altered gene signatures progression, and used complex molecular assays study the regulation in CRC cell lines, patient-derived xenograft mouse models organoid models. Results identified novel RNA-binding protein, RALY (also known as hnRNPCL2), that highly associated with...
N6-methyladenosine (m6A) is the most pervasive RNA modification and recognized as a novel epigenetic regulation in metabolism. Although m6A involves various physiological processes, its roles drug resistance colorectal cancer (CRC) still remain unknown. We analyzed expression profile of m6A/A (%) with MRM mass spectrometry human 5-fluorouracil (5-FU)-resistant CRC tissues, used immunoprecipitation assay to validate m6A-regulated target. Our results have shown that demethylase FTO was...
Epitranscriptomic modifications, particularly N6-methyladenosine (m6A), are crucial regulators of gene expression, influencing processes such as RNA stability, splicing, and translation. Traditional computational methods for detecting m6A from Nanopore direct sequencing (DRS) data constrained by their reliance on experimentally validated labels, often resulting in the underestimation modification sites. Here, we introduce pum6a, an innovative attention-based framework that integrates...
Lenvatinib, a second-generation multi-receptor tyrosine kinase inhibitor approved by the FDA for first-line treatment of advanced liver cancer, facing limitations due to drug resistance. Here, we applied multidimensional, high-throughput screening platform comprising patient-derived resistant tumor cells (PDCs), organoids (PDOs), and xenografts (PDXs) identify susceptibilities conquering lenvatinib resistance in clinically relevant settings. Expansion passaging PDCs PDOs from patient tumors...
Novel strategies in intratumoral injection and emerging immunotherapies have heralded a new era of precise cancer treatments. The affinity SARS-CoV-2 to ACE2 receptors, feature which facilitates virulent human infection, is leveraged this research. Colon cells, with their high expression, provide potentially strategic target for using feature. While the highly expression observed several types, idea viral spike protein targeting colon cells offers novel approach treatment. Intratumoral...